A 62-year-old with NYHA class II HFrEF (EF 30%), eGFR 55 mL/min/1.73 m², on maximally tolerated guideline-directed therapy (carvedilol, sacubitril/valsartan, spironolactone, loop diuretic) presents for optimization. Which addition reduces HF hospitalization and CV death independent of diabetes?